BlackRock
ACXP icon

BlackRock’s Acurx Pharmaceuticals ACXP Stock Holding History

BlackRock’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223 Hold
60
– – ﹤0.01% 5590
2025
Q4 		$149 Hold
60
– – ﹤0.01% 5463
2025
Q3 		$257 Hold
60
– – ﹤0.01% 5383
2025
Q2 		$615 Sell
60
-1,652
-96% -$13.3K ﹤0.01% 5372
2025
Q1 		$13.4K Buy
1,712
+416
+32% +$5.61K ﹤0.01% 5143
2024
Q4 		$21.1K Sell
1,296
-131
-9% -$3.94K ﹤0.01% 5093
2024
Q3 		$54.2K Buy
1,427
+52
+4% +$2.2K ﹤0.01% 4796
2024
Q2 		$61.9K Buy
1,375
+441
+47% +$19.4K ﹤0.01% 4814
2024
Q1 		$45.8K Sell
934
-2,222
-70% -$144K ﹤0.01% 4889
2023
Q4 		$242K Buy
3,156
+2,250
+248% +$170K ﹤0.01% 4589
2023
Q3 		$27.2K Sell
906
-38
-4% -$1.45K ﹤0.01% 5101
2023
Q2 		$50K Buy
944
+136
+17% +$8.1K ﹤0.01% 5066
2023
Q1 		$55.9K Buy
808
+26
+3% +$1.9K ﹤0.01% 5097
2022
Q4 		$62.2K Buy
782
+5
+0.6% +$329 ﹤0.01% 5169
2022
Q3 		$47K Sell
777
-22
-3% -$1.65K ﹤0.01% 5373
2022
Q2 		$61K Sell
799
-36
-4% -$2.42K ﹤0.01% 5370
2022
Q1 		$55K Buy
835
+501
+150% +$39.3K ﹤0.01% 5404
2021
Q4 		$29K Buy
334
+8
+2% +$761 ﹤0.01% 5498
2021
Q3 		$33K Buy
+326
New +$33.6K ﹤0.01% 5340

Other funds holding ACXP

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

BlackRock's ACXP Position: Q1 2026 in Review

BlackRock held its Acurx Pharmaceuticals (ACXP) position steady in Q1 2026 at 60 shares worth $223. The position accounts for ﹤0.01% of the portfolio, ranked #5590.

BlackRock first reported a position in ACXP in Q3 2021 and has held it in 19 quarters since. The position peaked at $242K in Q4 2023. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

  • BlackRock held 60 shares of Acurx Pharmaceuticals worth $223 as of Q1 2026.
  • BlackRock left its Acurx Pharmaceuticals share count unchanged in Q1 2026.
  • Acurx Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #5590 holding.
  • BlackRock first reported a position in Acurx Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • BlackRock's Acurx Pharmaceuticals position peaked at $242K in Q4 2023.
  • 21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.